Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Buy the Puma Biotechnology (PBYI) Dip - Citi
May 10, 2018 12:32 PM EDTCiti analyst Yigal Nochomovitz came out to defend Puma Biotechnology (NASDAQ: PBYI), saying the sell-off is overdone and to buy the dip.
He said the Possible explanations in order of likelihood 1) Lower apparent demand (NRx / new specialty pharmacy pt adds) in April (~230 / 280) vs. March (~300 / 342), 2)... More
